Skip to main content
OpenTrials
Completed

NCT Number: NCT01688622

Glypican4 and CTRP5 in Metabolic Syndrome and the Effect of Exercise on These Adipokines

Glypican4, CTRP3, CTRP5 are emerging novel adipokines mediating obesity and inflammation related disorders. RBP4 and adiponectin are well known important adipokines. Therefore, we examine the circulating levels of theses adipokines in the subjects with or without metabolic syndrome. Furthermore, we tried to clarify the effect of exercise on the circulating these adipokines.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metabolic Syndrome Body Weight Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Korea University Guro Hospital

Seoul, South Korea

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women between 30 and 60 years of age who had a body mass index (BMI) more than 25 kg/m2
  • The subjects of metabolic syndrome and age, gender matched non metabolic syndrome among the participants of Korean SO Study (KSOS) study, which is an ongoing epidemiologic study supported by the Korea Science and Engineering Foundation

Exclusion criteria

  • participants had a history of cardiovascular disease
  • any type of diabetes
  • stage 2 hypertension
  • malignant disease, severe renal, or hepatic disease
  • Subjects taking medications that might affect body weight or body composition

Treatment and study plan

3months Exercise

Behavioral

training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.

Primary outcomes

  1. The changes of circulating glypican4 levels after 3 months exercise

    Time frame: baseline and 12weeks

  2. The changes of circulating CTRP3 levels after 3 months exercise

    Time frame: baseline and 12weeks

  3. The changes of circulating CTRP5 levels after 3 months exercise

    Time frame: baseline and 12weeks

  4. The changes of circulating RBP4 levels after 3 months exercise

    Time frame: baseline and 12weeks

  5. The changes of circulating adiponectin levels after 3 months exercise

    Time frame: baseline and 12weeks

Secondary outcomes

  1. Circulating glypican4 levels in the subjects with or without metabolic syndrome

    Time frame: baseline

  2. Circulating CTRP3 levels in the subjects with or without metabolic syndrome

    Time frame: baseline

  3. Circulating CTRP5 levels in the subjects with or without metabolic syndrome

    Time frame: baseline

  4. Circulating RBP4 levels in the subjects with or without metabolic syndrome

    Time frame: baseline

  5. Circulating adiponectin levels in the subjects with or without metabolic syndrome

    Time frame: baseline

Sponsors and collaborators

Lead sponsor

Korea University

Other

Registry information

Official study title

Effects of Exercise on Glypican4,CTRP3,5 and RBP4 Levels and Circulating Levels of These Adipokines in the Subjects With or Without Metabolic Syndrome

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Sep 20, 2012
Registry last updated
Sep 21, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.